Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | MAP3K12 | Q12852 | 5/20 | 0.35 |
| ▸ | ACACB | O00763 | 5/20 | 0.35 |
| ▸ | MAP3K13 | O43283 | 2/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10204468 | 0.82 | KMT2A (0.40) | MAP3K12ACACB | |
| SCHEMBL624273 | 0.82 | KMT2A (0.40) | MAP3K12ACACB | |
| SCHEMBL622939 | 0.81 | SLC6A7 (0.35) | MAP3K12MAP3K13TLR9TLR8TLR7 | |
| SCHEMBL15006637 | 0.81 | PBRM1 (0.32) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL11963491 | 0.76 | HDAC1 (0.35) | MAP3K12MAP3K13HDAC1 | |
| SCHEMBL5889181 | 0.76 | MAP3K12 (0.39) | MAP3K12MAP3K13HDAC1 | |
| SCHEMBL11963315 | 0.76 | SLC6A7 (0.38) | MAP3K12MAP3K13HDAC1 | |
| SCHEMBL10204470 | 0.76 | CHRNB2 (0.44) | — | |
| Hydrochloric Acid SCHEMBL622360 | 0.75 | CHRNB2 (0.43) | — | |
| SCHEMBL12818162 | 0.73 | CCR2 (0.46) | MAP3K12ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999974-B2 | Acyl piperazine derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-04-07 | — | — | US | disclosed |
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | RAQUALIA PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2012020567-A1 | ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150356-A1 | Acyl Piperazine Derivatives as TTX-S Blockers | SCN5A, SCN2A, CACNA1G | HTR3E 2984/4885HTR3B 2170/4885HTR3A 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.